BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
76.80
-0.56 (-0.72%)
At close: Nov 17, 2026, 4:00 PM EST
76.76
-0.04 (-0.05%)
After-hours: Nov 17, 2026, 5:52 PM EST
BridgeBio Pharma Stock Forecast
Stock Price Forecast
According to 22 analysts polled by S&P Global, BridgeBio Pharma stock has a consensus rating of "Buy" and an average price target of $107. The average 1-year stock price forecast is 39.32% higher than the current stock price, while the lowest is $80 (+4.17%) and the highest is $156 (+103.13%).
Price Target: $107 (+39.32%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 14 | 14 | 14 | 14 | 14 |
| Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Hold | 2 | 2 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 22 | 22 | 22 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $88 → $91 | Buy | Maintains | $88 → $91 | +18.49% | Nov 13, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $106 → $108 | Buy | Maintains | $106 → $108 | +40.63% | Nov 2, 2026 |
| Barclays | Barclays | Buy Maintains $156 | Buy | Maintains | $156 | +103.13% | Nov 2, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 30, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $100 | Buy | Maintains | $100 | +30.21% | Oct 30, 2026 |
Financial Forecast
Revenue This Year
1.10B
from 502.08M
Increased by 118.56%
Revenue Next Year
1.66B
from 1.10B
Increased by 51.71%
EPS This Year
-2.45
from -3.78
EPS Next Year
-0.27
from -2.45
EPS and Forward PE are based on non-GAAP adjusted numbers.